PathCision Medicine develops targeted therapies for complex diseases by integrating tissue pathology insights with computational pathology. Their platform utilizes machine learning and deep biological understanding to discover innovative drug targets. This approach aims to transform treatment paradigms for previously incurable diseases, starting with metastatic cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Metastatic cancers are difficult to treat because they have spread from the primary tumor site, often developing resistance to conventional therapies. Current cancer treatments may lack the precision needed to selectively target metastatic cells while sparing healthy tissue, leading to significant side effects and limited efficacy.
Solution
PathCision Medicine is developing a new class of antibody-drug conjugates (ADCs) designed to selectively target and eradicate metastatic cancer cells. Their approach leverages insights from tissue pathology to identify unique markers expressed on metastatic cells but not on healthy cells. By conjugating potent cytotoxic drugs to antibodies that bind to these markers, PathCision aims to deliver a targeted payload directly to the metastatic tumor microenvironment. This precision targeting minimizes off-target effects, potentially improving treatment outcomes and reducing toxicity for patients with advanced cancers. The company's goal is to transform the treatment of previously incurable metastatic diseases by providing healthcare providers with more effective and selective therapeutic options.
Target Audience
The primary target audience includes healthcare providers, specifically oncologists, who treat patients with metastatic cancers, as well as patients with advanced cancers who have limited treatment options.
Features
- Antibody-drug conjugates (ADCs) that selectively target metastatic cancer cells.
- Tissue pathology-driven approach to identify unique markers on metastatic cells.
- Conjugation of potent cytotoxic drugs to antibodies for targeted delivery.
- Designed to minimize off-target effects and reduce toxicity.